Park Won-joo, Commissioner of the Korean Intellectual Property Office, Visits DinoNA, a COVID-19 Research Company
[Asia Economy Reporter Hyunseok Yoo] Park Won-joo, Commissioner of the Korean Intellectual Property Office (KIPO), visited Celltrion on the 30th of last month and then visited DynoNA, a developer of antibodies for the treatment of COVID-19, on the 3rd to hear voices from the field. DynoNA is a subsidiary of SMAC.
According to KIPO, during the meeting that day, DynoNA explained its development strategy for a treatment for acute respiratory distress syndrome (ARDS) related to cytokine storms in COVID-19 patients through neutrophil depletion. Having already filed patents related to neutrophil depletion in cancer patients, DynoNA plans to file additional patents related to viral acute respiratory distress syndrome. In this regard, Park Won-joo showed deep interest and agreed to actively cooperate in the patent process.
Additionally, DynoNA, through an introduction by KIPO, directly participated the day before in a demand survey for a COVID-19 virus-infected monkey test model at the COVID-19 Virus Research Committee within the National Primate Research Center of the Korea Research Institute of Bioscience and Biotechnology. As a result, DynoNA expressed its intention to join the government-level COVID-19 virus therapeutic development project and proceed actively with therapeutic development.
Hot Picks Today
"Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Is This Car Waterproof?" US Man in His 70s Makes Dramatic Escape After Driving Cybertruck Into Lake, Trusting Its Features
- Appearing in a Leather Jacket, Jensen Huang Hastily Eats $6 Noodles on the Street... Shop Instantly Becomes a Hotspot
Separately, DynoNA has completed a technical review to discover neutralizing antibodies against the COVID-19 virus from the blood of patients who have recovered from COVID-19 infection. By simultaneously pursuing two approaches?developing antibodies that directly block the COVID-19 virus and antibodies for treating acute respiratory distress syndrome (ARDS) using the human immune system?DynoNA is advancing one step closer to developing a COVID-19 virus therapeutic.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
